Priaxon is an emerging drug discovery company with unique and proprietary drug discovery platform using two orthogonal technologies. Priaxon has a strong focus on small molecule modulators of protein protein interactions. The company can exhibit a successful track record in this field which is highlighted by the partnering of the mdm2/p53 inhibitor program with Boehringer Ingelheim.
Priaxon has a strong network of inhouse and external competence in oncology applications.
Further areas of interest are innovative hybrid antiinfectives against nosocomial infections.
Priaxon's approach to generate value is characterized by a unique drug discovery engine using a prorietary combination of chemoinformatic tools with innovative synthetic chemistries.
Applying the drug discovery engine Priaxon discovers and advances promising compounds to create a robust and sustainable pipeline of high impact small molecules.
- Focus on well validated but still thrilling targets for unmet medicinal needs
- Partnering of the discovered compounds at an early stage with global pharmaceutical companies having the capacity and expertise to develop the programs straight towards their clinical trials
- Extraordinary interest in the future field of the discovery and development of small molecule inhibitors for protein protein interactions, especially in oncology
Building Blocks 
